Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEY7T4)

• Drug Name: ONO-AE3-208 Drug Info
• Synonyms: 402473-54-5; 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]benzenebutanoic acid; ONO AE3 208; SCHEMBL679969; GTPL1942; CTK1D4873; KS-00001DVO; DTXSID20435810; MolPort-035-765-695; 3952AH; AKOS024457689; 4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic Acid; CS-0315; NCGC00378671-02; HY-50901; AK547789; DB-030557; FT-0715398; ONO-AE3-208, > W-5560; 473O545; 4-(4-Cyano-2-(2-(4-fluoronaphthalen-1-yl)propanamido)phenyl)butanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 10111831
  CAS Number: CAS 402473-54-5
  TTD Drug ID: DMEY7T4

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[3]
RQ-00000007 (oral)	DMMYTRU	Pain	MG30-MG3Z	Phase 2	[4]
ONO-AE1-437	DMCUGI8	Asthma	CA23	Phase 2	[5]
BGC-20-1531	DMS2MQ5	Migraine	8A80	Phase 2	[6]
IK-007	DMBLFPN	Non-small-cell lung cancer	2C25	Phase 1/2	[7]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
E7046	DMFVT43	Rectal adenocarcinoma	2B92	Phase 1	[9]
ONO-4232	DMO4SD2	Acute heart failure	BD10-BD13	Phase 1	[10]
ONO-4578	DME63VK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
AN0025	DMGSYPY	Aggressive cancer	2A00-2F9Z	Phase 1	[11]

Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[3]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[12]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[3]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[13]
DG041	DMVO9WM	Peripheral vascular disease	BD4Z	Discontinued in Phase 2	[14]
GR-63799X	DM13GK8	Asthma	CA23	Discontinued in Phase 1	[15]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[16]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[3]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[17]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin E2 receptor EP3 (PTGER3)	TTPNGDE	PE2R3_HUMAN	Antagonist	[2]
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Antagonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1942).
• [2] The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93.
• [3] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [4] Clinical pipeline report, company report or official report of Avarx.
• [5] An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
• [6] BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
• [7] Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
• [8] Clinical pipeline report, company report or official report of Tempest Therapeutics.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
• [11] AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
• [12] IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
• [13] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [14] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [15] Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
• [16] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [17] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.